PRESENTATION · Dec 2024 · PDF

BBP-418 - WMS 2024 - FORTIFY Design

PRESENTATION · Dec 2024 · PDF

Canavan GTx BBP-812 - ESGCT 2024 - Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Costs and healthcare resource utilization in ATTR-CM exceeds that of non-amyloid heart failure

PRESENTATION · Dec 2024 · PDF

BBIO - Infigratinib - PROPEL 2 Data Update and ACCEL Program Initiation

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ASBMR 2024 Preliminary Findings from Ongoing Open Label Phase 2 Study

PRESENTATION · Dec 2024 · PDF

BBP-418 - MENA 2024 - Oral Presentation

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Evolving baseline risk in patients with ATTR-CM: a systematic literature review of clinical trials

PRESENTATION · Dec 2024 · PDF

Encaleret- Chronic Hypoparathyroidism- ENDO 2024 Preliminary Findings From an Ongoing Open-label Phase 2 Study on Relationship Between Blood and Urinary Calcium in Individuals with Post-surgical Hypoparathyroidism

PRESENTATION · Dec 2024 · PDF

BBP-418 - MDA 2024 - FORTIFY Phase 3 Trial Design

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Relationship between CVH and survival in the acoramidis-treated participants within ATTRibute-CM